Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Japan Units of Abbott, Mylan to Run Separate Operations for Now
March 4, 2015
- Almac Aims to Expand Japan Business
March 4, 2015
- Santen Files Sirolimus for Noninfectious Uveitis in Europe
March 4, 2015
- Chugai, Athersys Join Hands for Cell Therapy Treatment
March 4, 2015
- Taiho Files Lonsurf for EU Approval
March 4, 2015
- Torii to Market 2 Anti-HIV Drugs Containing Tenofovir Alafenamide in Japan
March 3, 2015
- Switch OTC Drug Market Grows to 162 Billion Yen in 2014: Fuji Keizai
March 3, 2015
- Novartis Offers Apologies over Biz Suspension, Vows to Prevent Recurrence
March 2, 2015
- Jinarc Approved for Autosomal Dominant Polycystic Kidney Disease in Canada: Otsuka
March 2, 2015
- Eli Lilly Aims to Lead Japan Diabetes Market by 2020
March 2, 2015
- MTPC Eyes Total Sales of Over 100 Billion Yen for Remicade, Simponi
February 27, 2015
- Takeda Launches Takecab, to Copromote with Otsuka
February 27, 2015
- Medicago Signs Up with US Govt Agency for Development of Production Process for Ebola Antibodies
February 27, 2015
- Shionogi to Reorganize in April to Beat Biz Strategy Goals for FY2020
February 26, 2015
- Avigan Shows Promise in Treatment of Ebola in Clinical Trial
February 26, 2015
- NanoCarrier Concludes Joint Research Agreement with Chugai to Develop Next-Generation Anticancer Drugs
February 26, 2015
- Eisai to File Halaven for Soft Tissue Sarcomas; PIII Study Results Show Significant Prolongation of OS
February 26, 2015
- Takeda to Acquire Turkish Firm for Up to 14.5 Billion Yen, Earn 13 Branded Generics
February 25, 2015
- Daiichi Sankyo to Shake Up Japan Organization as Olmetec Patent Expiry Nears
February 25, 2015
- Japan’s 6th SGLT-2 Inhibitor Jardiance Hits Market
February 25, 2015
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…